CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Oct 17, 2023

Keywords

ClinConnect Summary

The CAPACITY Study is looking at how exercise training can help people with cardiac amyloidosis, a condition that affects the heart's ability to function properly. The trial will explore whether regular physical activity can improve fitness and overall quality of life for patients with heart failure, particularly those whose heart function is still preserved.

To participate, individuals must be at least 18 years old and have a diagnosis of heart failure that is classified as NYHA Class I-III, which means their symptoms are mild to moderate. They should be able to exercise and be on stable treatment for their condition. Participants will attend supervised exercise sessions three times a week for 12 weeks, where they will engage in activities designed to improve their heart health. It's important to note that those with advanced heart failure, breathing issues that require oxygen at home, or significant balance problems may not be eligible. This study is currently recruiting participants, and interested individuals should have a life expectancy of at least six months and be willing to follow the program guidelines.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18
• • New York Heart Association (NYHA) Class I-III Heart Failure
• • Able to Exercise
• • On stable treatment for their cardiac amyloidosis or under active surveillance
• • Life expectancy of at least 6 months
• • Ability to understand and the willingness to sign a written informed consent document in English, and the willingness/ability to comply with the protocol activities
• • Participant must be able and willing to follow the cardiac rehabilitation activities
• Exclusion Criteria:
• • Inability to provide informed consent
• • Inability to commit to in-person supervised exercise sessions for three one-hour sessions a week for 12 weeks
• • NYHA Class IV Heart Failure
• • Pulmonary disease requiring home oxygen
• • Gait instability or history of prior falls
• • In the opinion of the Principal Investigator, have a clinically significant comorbid disease that is likely to affect the ability of the patient to complete the trial, interfere with their ability with measurement of self-reported outcomes.